ELV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
ELV looks like a good buy right now for a beginner with a long-term horizon and $50,000-$100,000 to invest. The stock has constructive momentum, supportive analyst revisions, positive insider buying, favorable congress activity, and improving managed-care sentiment. The current price is near resistance but still within a reasonable entry zone for a long-term investor who does not want to wait for perfect timing. My view: buy.
Technically, ELV is in an uptrend. The MACD histogram is positive and expanding, which confirms improving momentum. RSI at 72.493 suggests the stock is strong and near overbought territory, but not a reversal signal by itself. Moving averages are converging, which suggests the stock may be transitioning into a more stable trend rather than a sharp breakout. Price at 413.3 is close to first resistance at 418.822, with support at 401.269 and then 383.716. The short-term setup is constructive, and the recent SwingMax entry signal adds confirmation that the current area is a valid entry point.
["Bernstein raised target to $482 and kept Outperform, with expectations for strong Q2 EPS and a modest MLR beat.", "BofA raised target to $460 and turned more bullish on managed care names.", "Deutsche Bank upgraded ELV to Buy with a $498 target, citing a stabilizing managed care market.", "SwingMax sent an entry signal on 2026-07-01, supporting a buy-the-dip/buy-the-trend setup.", "Insiders are buying, with buying up 132.13% over the last month.", "Congress members made 1 purchase and 0 sales in the last 90 days, signaling positive political sentiment.", "Recent news on a national agreement with Plus Therapeutics' CNSide Diagnostics is mildly positive for business development and market reach."]
["Hedge funds are selling, with selling up 135.25% over the last quarter.", "RSI is elevated at 72.493, meaning the stock is somewhat extended in the short term.", "The stock is trading close to resistance around 418.822, which could slow immediate upside.", "Wells Fargo noted remaining steps tied to earlier CMS/Medicare Advantage sanctions concerns, even though immediate sanctions were not expected.", "Evercore still had an In Line rating and expressed caution about possible Medicaid headwinds in 2027."]
No usable latest-quarter financial snapshot was provided because the financial data section returned an error. So I cannot assess the actual reported quarter results directly from the dataset. However, analyst commentary suggests the latest quarter environment was favorable, with expectations for strong adjusted EPS, manageable medical loss ratio trends, strong Medicare Advantage performance, and solid commercial business trends. The mention of Q2 expectations indicates the latest quarter in focus is Q2 2026.
Analyst sentiment has turned more positive over the past month. Multiple firms raised price targets: Bernstein to $482, BofA to $460, Truist to $450, Barclays to $480, Mizuho to $435, and Deutsche Bank upgraded to Buy with a $498 target. Morgan Stanley remained more neutral at Equal Weight with a $404 target, and Evercore stayed In Line with $360. Overall Wall Street leans bullish: the pros argue for improving managed care trends, muted cost pressures, margin recovery, and achievable 2026 estimates. The main cons are lingering Medicaid risk, some regulatory uncertainty tied to CMS/MA issues, and a few neutral-rated firms that do not fully confirm the upside.
